Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

1.01
-0.0550-5.19%
Volume:2.95M
Turnover:2.96M
Market Cap:340.21M
PE:-3.94
High:1.06
Open:1.05
Low:0.9916
Close:1.06
52wk High:2.73
52wk Low:0.9916
Shares:338.52M
Float Shares:327.56M
Volume Ratio:0.65
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-20.55
PE(LYR):-4.45

Loading ...

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

MT Newswires Live
·
Apr 01

Ocugen completes dosing in GARDian3 trial

TIPRANKS
·
Apr 01

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

Reuters
·
Apr 01

BUZZ-Ocugen rises after finishing patient dosing in late-stage eye gene therapy trial

Reuters
·
Apr 01

Ocugen completes dosing in Phase 2/3 Stargardt gene therapy trial ahead of schedule

Reuters
·
Apr 01

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Apr 01

Ocugen Inc. Stock Slips 6.4%, Underperforms Market

Dow Jones
·
Mar 31

Ocugen Inc. Stock Sheds 4.6%, Underperforms Market

Dow Jones
·
Mar 28

Assessing Ocugen (OCGN) Valuation After Recent Share Price Volatility And Long Term Momentum

Simply Wall St.
·
Mar 27

Canaccord Genuity Sticks to Its Buy Rating for Ocugen (OCGN)

TIPRANKS
·
Mar 26

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Mar 26

Ocugen: Encouraging Phase 2 OCU410 Data in Geographic Atrophy Underpin Buy Rating and Long-Term Upside Potential

TIPRANKS
·
Mar 26

Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi‑Year Share Price Swings

Simply Wall St.
·
Mar 25

Ocugen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Ocugen price target raised to $10 from $7 at H.C. Wainwright

TIPRANKS
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy

MT Newswires Live
·
Mar 24

BUZZ- Ocugen rises as gene therapy slows vision loss in advanced eye disease trial

Reuters
·
Mar 24

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

TIPRANKS
·
Mar 24

Ocugen reports 31% lesion growth reduction at 12 months in Phase 2 ArMaDa trial of OCU410 for geographic atrophy

Reuters
·
Mar 24